You can buy or sell CALA and other stocks, options, ETFs, and crypto commission-free!
Calithera Biosciences, Inc. engages in discovering and developing small molecule drugs that that target novel and critical metabolic pathway in tumor and cance-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. Read More The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Seeking AlphaMar 8
Calithera Biosciences (CALA) CEO Susan Molineaux on Q4 2018 Results - Earnings Call Transcript
Calithera Biosciences (NASDAQ:CALA) Q4 2018 Earnings Conference Call March 7, 2019 4:30 PM ET Company Participants Jennifer McNealey - Vice President, Investor Relations and Strategy Susan Molineaux - Founder, President and Chief Executive Officer Stephanie Wong - Senior Vice President, Finance Keith Orford - Chief Medical Officer Conference Call Participants Matt Phipps - William Blair Srikripa Devarakonda - Citigroup Jonathan Chang - SVB Leerink Operator Good day, ladies and gentlemen and thank...
Associated PressMar 5
Calithera to Present at Cowen & Company 39th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan M. Molineaux, Ph.D, the company’s founder, president and chief executive officer, will present at the Cowen & Company 39th Annual Healthcare Conference at 10:40 a.m. ET on Tuesday, March 12, 2019 in Boston. T...
Markets InsiderFeb 21
Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it has initiated a Phase 1 clinical trial with CB-280, a novel, orally dosed arginase inhibitor being developed for the treatment of cystic fibrosis (CF). “The initiation of this Phase 1 study with CB-280 marks a...
-$0.49 per share
-$0.51 per share